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ABSTRACT 
The incidence of inflammatory bowel disease is increasing worldwide and the underlying molecular 
mechanisms are far from being fully elucidated. Herein, we evaluated the role of N-glycosylation 
dysregulation in T cells as a key mechanism in the ulcerative colitis (UC) pathogenesis. The 
evaluation of the branched N-glycosylation levels and profile of intestinal T cell receptor (TCR) were 
assessed in colonic biopsies from UC patients and healthy controls. Expression alterations of the 
glycosyltransferase gene MGAT5 were also evaluated. We demonstrated that UC patients exhibit a 
dysregulation of TCR branched N-glycosylation on lamina propria T lymphocytes. Patients with 
severe UC showed the most pronounced defect on N-glycan branching in T cells. Moreover, UC 
patients showed a significant reduction of MGAT5 gene transcription in T lymphocytes. In this 
study, we disclose for the first time that a deficiency in branched N-glycosylation on TCR due to a 
reduced MGAT5 gene expression is a new molecular mechanism underlying UC pathogenesis, being 
a potential novel biomarker with promising clinical and therapeutic applications. 
INTRODUCTION  
Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal 
tract that includes ulcerative colitis (UC) and Crohn's disease (CD) (1). The incidence of IBD is 
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increasing worldwide and the disease remains incurable. IBD places a heavy burden on populations 
reducing quality of life and incurring substantial medical and societal costs (2). Although progress 
has been made in understanding the disease, the etiopathogenesis of IBD is far from being fully 
elucidated. Accumulating evidence suggests that IBD results from an inappropriate inflammatory 
response in a genetically susceptible host (1,3), although the underlying molecular mechanisms 
remain elusive. 
UC is a chronic inflammatory condition causing continuous mucosal inflammation of the colon 
affecting the rectum and a variable extent of the colon in continuity, which is characterized by a 
relapsing and remitting course. The inflammation in UC is typically confined to the mucosa (1,2), 
and the course of the disease is characterized by flares that alternate with periods of remission. 
Severity of flares and their response to treatment vary and are hard to predict. In addition, 
prognosis of patients with UC is difficult to determine (2). In line with this, it is of paramount 
importance to further identify and characterize the underlying molecular mechanisms of UC 
pathogenesis in order to improve the development of novel biomarkers that may help the 
determination of prognosis and also improve the patients’ stratification for appropriate treatment 
(4). 
Glycosylation is a complex post-translational mechanism characterized by the addition of 
carbohydrate structures (glycans) to proteins and lipids in the endoplasmic reticulum/Golgi 
secretory pathway, by specific enzymes (glycosyltransferases) (5). The immune system is tightly 
controlled by cellular glycosylation as almost all of the key molecules involved in innate and 
adaptive immune responses are glycoproteins (6–8). The N-acetylglucosaminyltransferase V (GnT-
V) is a glycosyltransferase encoded by the human MGAT5 gene that catalyses the synthesis of β1,6 
GlcNAc branched N-glycans structures, which are known to play pivotal roles in many glycoproteins 
in cancer (9,10), and particularly in T cell function (11). This N-glycan branch commonly includes 
polylactosamine chains (N-acetyllactosamine disaccharide repeats) that are ligands for various 
lectins of the galectin family (12). Mice deficient in the MGAT5 gene have been shown to develop 
autoimmune diseases, increased delayed-type hypersensitivity responses and an enhanced 
susceptibility to experimental autoimmune encephalomyelitis (EAE, a mouse model of multiple 
sclerosis) (13–15). These mice lacking GnT-V function (no synthesis of β1,6GlcNAc branched N-
glycans structures) display a significantly increased T cell receptor (TCR) clustering, leading to a 
decreased threshold of T cell activation, and increased TH1 differentiation resulting in hyperimmune 
response and increased susceptibility to autoimmunity (16,17). Overall, these reports support that T 
cell activity and signaling is tightly regulated by GnT-V-mediated glycosylation. In fact, in 
homeostasis and self-tolerance, T cell activation (TCR signaling) induces up-regulation 
of MGAT5 gene which in turns leads to GnT-V-mediated glycosylation of the TCR (18). This 
phenotype promotes growth arrest of T cells by at least two mechanisms: early, by raising T cell 
activation thresholds via limiting TCR clustering at the immune synapse and the consequent 
hyperimmune response, and later by increasing surface retention of growth inhibitory receptors 
such as cytotoxic T lymphocyte antigen-4 (CTLA-4) (18). 
The abovementioned evidences in other immune-mediated disorders set the ground to the present 
study that aims to address for the first time whether the dysregulation of this critical interplay 
between N-glycan branching and T cell activity is a major contributory factor and a yet uncovered 
mechanism underlying UC. In this study, we first report that dysregulation of the GnT-V-mediated 
glycosylation of the TCR on lamina propria T cells is a new molecular mechanism underlying UC 
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pathogenesis. We further showed that UC patients exhibit a deficiency in T 
lymphocytes MGAT5gene transcription comparing with normal controls, which underlies the 
observed dysregulation of T cell glycosylation in UC. 
RESULTS 
Active UC cases exhibit a decreased expression of branched N-glycans in intestinal lymphocytic 
infiltrates 
We first evaluated whether there were alterations in the expression of β1,6 GlcNAc branched N-
glycans structures in intestinal lamina propria lymphocytic infiltrates positive for CD3 expression in 
a well-characterized series of colonic biopsies (n = 64) from UC patients comparing with normal 
controls. By using L-PHA lectin histochemistry, we observed that active UC cases had significantly 
lower expression (P < 0.0001) of branched N-glycans in intestinal lamina propria cell infiltrates CD3
+
, 
when compared with normal controls (Table 1, Fig. 1A and B). UC patients with inactive disease 
(Mayo subscore 0), which have a controlled T cell response, showed increased expression of 
lymphocytic branched N-glycans expression (Table 1) comparing with active UC (Mayo subscore 
≥1), but a tendency to have less lymphocytic N-glycans expression levels than normal controls. In 
the controls, the lamina propria lymphocytes (LPLs) CD3
+
 exhibit high expression of L-PHA lectin 
(Table 1, Fig. 1A and B). No differences were observed comparing the levels of L-PHA expression 
with age, gender and disease extension. These results showed significant alterations of β1,6 GlcNAc 
branched N-glycans expression in the intestinal lymphocytic infiltrate of UC cases comparing with 
normal controls. The variability in branched N-glycans expression on T cells among active and 
inactive UC is in accordance with disease severity. All of the severe UC cases (Mayo subscore 3) 
showed the lowest expression (<25%) of lymphocytic branched N-glycans. Moreover, we have 
observed that, for the same patient and during the course of disease, the percentage of expression 
of lymphocytic branched N-glycans varies accordingly with disease severity. These results were 
next explored in-depth at the molecular level. 
Levels of TCR and CD3 expression in UC patients and normal controls: phenotypic 
characterization of T cells subsets and activation state 
The results showed increasing levels of TCRβ and CD3 protein expression from normal controls; 
inactive UC (Mayo subscore 0); to active UC patients (Mayo subscore ≥1). The severe UC patients 
(Mayo subscore 3) had the higher levels of both TCRβ and CD3 proteins of the analyzed samples 
groups (Fig. 2A). The TCRβ and CD3 protein expression levels correlated with the clinical criterions; 
Mayo endoscopic subscoring and the histological standards for these setting of patients. In 
addition, the isolated T cells obtained from the fresh colonic biopsies were analyzed by imaging 
flow cytometry analysis (Fig. 2C). The results showed that the expression of TCR from isolated cells 
were higher in active UC patients comparing with normal controls (Fig. 2C), validating the results 
obtained by western blot (Fig. 2A and B). 
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The phenotypic characterization of the T cells subsets showed that the intestinal T cell lymphocytic 
infiltrate from UC patients is predominantly represented by CD4
+
 T cells, whereas in the normal 
individuals the intestinal T cells population is predominantly CD8
+
 (Fig. 2D and E). Curiously, 
intestinal T cells from patients with UC had higher levels of TCR-alpha/beta expression when 
compared with intestinal T cells from controls (Fig. 2C and D), this being more evident in CD4
+
 T 
cells than in CD8
+
 T cells (data not shown). In addition, both normal and UC intestinal T cells express 
activation-related markers, HLA-DR and CD45RO (Fig. 2D and E). However, intestinal T cells from 
UC patients exhibit a higher level of expression of these activation-related markers compared with 
controls, as evaluated by the median fluorescence intensity (MFI) of the antigen expression 
(Fig. 2E). 
TCRs from UC patients exhibit a decreased modification with β1,6 GlcNAc branched N-glycans 
structures 
In order to evaluate the levels of β1,6 GlcNAc branched N-glycans expression specifically on the 
TCR of LPLs from UC patients and controls, we performed different experimental approaches that 
mutually validate each other. On the one hand, we isolated the LPLs from a subset of fresh biopsies 
collected from UC patients and controls which were analyzed by the L-PHA blot. We demonstrated 
that the TCR was differently glycosylated with branched N-glycans compared with UC patients and 
normal controls (Fig. 3A and B). UC patients with active disease (Mayo subscore ≥1) showed a 
significant decrease in the levels of TCR modification with branched N-glycans when compared 
with controls. Patients with severe disease (Mayo subscore 3) displayed the lowest levels of TCR 
glycosylation. Moreover, the levels of branched N-glycans modification on the TCR surface 
decreased concomitantly with disease severity (from Mayo subscore 0 to 3) (Fig. 3A and B), as also 
observed by histochemistry (Table 1 and Fig. 1). The levels of bisecting GlcNAc structures (catalyzed 
by GnT-III) on the TCR did not vary significantly among UC patients and controls (Supplementary 
Material, Fig. S1). These results on the isolated LPLs were further validated, by performing TCR 
immunoprecipitation from the total protein lysate (TCL) of the UC and controls biopsies, followed 
by β1,6 GlcNAc branched N-glycans recognition (L-PHA blot) (Fig. 3C and D). The results 
demonstrated that UC patients (both with inactive and active disease) showed significant 
decreased levels of TCR glycosylation with branched N-glycan structures compared with normal 
controls. Again, patients with severe disease (Mayo subscore 3) showed the lowest levels of β1,6 
GlcNAc branched N-glycans on TCR. These observations obtained at the molecular level by two 
different technical approaches, pinpoint the existence of a dysregulation of intestinal TCR N-
glycosylation mediated by GnT-V in UC patients compared with controls, which appear to be 
associated with disease severity. Furthermore, we also confirm this dysregulation by imaging flow 
cytometry that combines features of both conventional flow cytometry and fluorescence 
microscopy and thus allows quantification of imaging parameters, including membrane intensity of 
different probes (19). Interestingly, we observed that isolated LPLs from active UC patients showed 
a decreased fluorescence intensity of L-PHA on the membrane of the TCRα/β positive cells than the 
one detected in normal controls (Fig. 4). These bioimaging observations corroborate the above 
results and further pointing toward a deficiency in TCR branched N-glycans in UC patients.  
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MGAT5 gene expression alterations in T cells from UC patients 
It has been demonstrated that TCR signaling regulates multiple Golgi N-glycan branching-
processing enzymes at the mRNA level, such as MGAT5 (18). Therefore, and in order to assess if the 
deficiency in TCR N-glycan branching, catalyzed by GnT-V, could be due to genetic alterations 
of MGAT5 glycogene, we evaluated the mRNA transcription levels of MGAT5 in a representative 
sub-series of intestinal LPLs isolated from active UC patients and normal controls (Fig. 5A and B). 
Our results consistently showed that LPLs from UC patients with active disease significantly express 
altered mRNA levels of MGAT5 compared with normal controls (Fig. 5). The MGAT5 mRNA analysis 
performed both independently (Fig. 5A) or using RNA pooled from different individuals (Fig. 5B) 
showed that LPLs from active UC patients had significantly lower levels of MGAT5 transcription 
than normal controls. No significant alterations were observed on MGAT3 transcription 
(Supplementary Material, Fig. S1). This is the first evidence suggesting the identification of a 
possible genetic alteration in the MGAT5 gene from LPLs, which appears to underlie the deficiency 
of TCR N-glycosylation associated with UC pathogenesis, an issue that is being further studied in 
larger cohort populations.  
DISCUSSION 
In the present study, we have disclosed a novel molecular mechanism contributing for UC 
pathogenesis. We demonstrated that UC patients have dysregulation of intestinal TCR N-
glycosylation, which has been associated with T cell hyperactivity and hyperimmune response 
(16,17). We further provide the first evidence supporting that UC patients exhibit a transcriptional 
alteration of the MGAT5 gene in intestinal LPLs that appear to be the causative mechanism for the 
deficiency on TCR N-glycosylation of these patients, which associates with, and may possibly 
determine disease severity or susceptibility. 
A growing body of evidence has demonstrated that in homeostasis and self tolerance, the T cell 
activation (TCR signaling) induces up-regulation of the MGAT5 gene which in turns leads to GnT-V-
mediated glycosylation of the TCR (18). The N-glycan branching on T cells, catalyzed by GnT-V 
glycosyltransferase, promotes the formation of multivalent galectin binding which negatively 
regulates T cell growth by precluding TCR clustering, and increasing the TCR activation thresholds, 
ultimately modulating the immune response (Fig. 6). Interestingly, recent evidences support that 
environmental and genetic dysregulation of N-glycosylation are involved in the molecular 
mechanism of human multiple sclerosis pathogenesis (15,20). In UC we consistently observed, both 
by immunohistochemistry and at molecular level, that UC patients exhibit a defective N-glycan 
branching on intestinal TCR compared with normal controls (Fig. 6). Interestingly, patients with 
severe forms of endoscopic activity (Mayo endoscopic subscore 3) showed the lowest levels of 
TCR N-glycan branching compared with patients with mild, moderate or inactive disease. This 
variability in the levels of TCR N-glycan branching among UC patients was demonstrated to 
accompany disease severity, which at the end may determine different susceptibilities to the 
different forms of UC. These data are in accordance with previous observations in models of EAE 
(21). The authors reported that among inbred mouse strains, N-glycan GlcNAc branching in T cells 
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was highly variable (different hypomorphic forms) and inversely correlated with EAE susceptibility 
(21). In addition, we observed that levels of TCR glycosylation are associated with different T cell 
subsets (predominantly represented by CD4
+
 T cells in UC patients and by CD8
+
 T cells in normal 
individuals) and with different levels of T cell activation (higher surface expression of HLA-DR and 
CD45RO on T cells from UC patients, when compared with controls). Lower levels of TCR 
glycosylation (in UC patients) were found in the intestinal T cell subsets that were predominantly 
represented by CD4
+
 T cells in an activated state. These differences on TCR branched glycosylation 
associated with different T cells subsets/activation (Fig. 2D and E) are in accordance with previous 
observations showing that CD4
+
 and CD8
+
 T cells have been shown to have different profiles of N-
linked glycans (22,23). Differential effects of glycosylation on specific T cell lineages have been 
reported previously. For instance, sialyltransferase ST3 Gal-I-deficient mice lacked CD8
+
, but not 
CD4
+
 T lymphocytes (24). Moreover, and in line with our observations, the disruption of N-
glycosylation by MGAT5 ablation has been shown to lower T lymphocyte activation thresholds and 
cause autoimmunity (17). Altogether, our results further support that the differential glycosylation 
of CD4
+
 versus CD8
+
 T cells could cause differential activation thresholds and/or mechanisms (23). In 
addition, these glycosylation differences in the T cells subsets compared UC patients and controls 
may have major impact on CD4
+
 versus CD8
+
 T cell differentiation and function. This issue should be 
further examined in the future. To further explore the possible causative mechanism of the 
dysregulation of the TCR branched N-glycosylation in UC patients, we evaluated the mRNA 
transcription levels of the MGAT5 gene (that encodes GnT-V enzyme). Interestingly, we consistently 
observed a reduced MGAT5 mRNA transcription levels in LPLs from UC patients with active disease 
compared with controls. These results support a genetic alteration of the MGAT5 gene from 
intestinal T lymphocytes of UC patients, being the underlying event that promotes a dysregulated 
immune response through a disturbance in protein branched N-glycosylation catalyzed by GnT-V 
on intestinal TCR (Fig. 6). Interestingly, and in line with our results, it has been proposed 
that MGAT5 is a gene that determines severity and susceptibility to multiple sclerosis (25,26). Our 
observations open new avenues for further exploring MGAT5 as a potential susceptibility gene in 
IBD pathogenesis. Nevertheless, whether this dysregulation of MGAT5/GnT-V-mediated 
glycosylation on TCR is a cause or consequence of the Ulcerative Colitis disease is a premature 
conclusion that deserves to be carefully addressed. 
In addition, the identification of a specific molecular mechanism underlying UC pathogenesis 
constitutes an opportunity to improve the target-specific therapy of UC patients. In fact, it was 
showed that metabolic supplementation of mice or T cells with UDP-GlcNAc enhances GlcNAc 
branching of T cells catalyzed by GnT-V which increases the threshold for T cell activation, 
suppresses T cell growth and inhibits Th1 differentiation leading to a controlled immune response 
and a decreased disease clinical severity in EAE and type I non-obese diabetic mice (27,28). 
Interestingly enough, a pilot study of oral GlcNAc in pediatric treatment-resistant IBD reveals the 
potential of GlcNAc as a therapeutic agent. In that pilot study, 8 out of 12 children with severe IBD 
went into clinical remission with evidence of histological improvement (29). Our results further 
contribute to explain the therapeutic effect of GlcNAc observed in pediatric IBD that was at that 
time unknown. The identification of an underlying disease mechanism prone to be targeted by 
specific therapy is a major unmet need for the management of IBD in general, enlarging the 
therapeutic options and improving the success of the therapy. In this regard, we are conducting 
further studies and controlled trials in order to test the therapeutic efficacy of this inexpensive and 
non-toxic agent in IBD. 
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In conclusion, our study demonstrates that dysregulation of branched N-glycosylation on TCR is a 
key mechanism in UC pathogenesis. Moreover, we identified that MGAT5 gene expression 
alterations underlie the observed defect on TCR branched N-glycosylation. This deficiency in T 
cells N-glycosylation is positively associated with disease severity. Taken together, the disclosure of 
this new molecular mechanism in UC disease opens new windows of opportunity to further explore 
the potential applicability of this mechanism in predicting disease course and/or susceptibility. In 
addition, our observations further suggest the potential of metabolic supplementation with GlcNAc 
as a promising therapeutic tool that directly targets an underlying mechanism. 
MATERIALS AND METHODS 
Patient selection and colonic biopsies collection 
The present study includes 30 patients from which 13 were normal controls and 17 were IBD 
patients diagnosed with UC that underwent scheduled colonoscopy (between 1991 and 2013) at the 
Gastroenterology Department of Centro Hospitalar do Porto-Hospital de Santo António 
(CHP/HSA), Porto, Portugal. The patients were randomly enrolled in the study prospectively from a 
cohort of outpatients of IBD clinics. All the 17 patients were studied: retrospectively by analyzing 
formalin-fixed paraffin-embedded (FFPE) samples at different stages of disease course/activity 
(obtained from the Pathology archive of CHP/HSA); and prospectively, where collected fresh 
colonic biopsies (8–20 biopsies per UC patient) were analyzed for different purposes: 
histology/morphology; isolation LPLs; protein and RNA extraction. From these 17 UC patients, we 
have analyzed 51 colonic biopsies (FFPE samples) that were collected at different times of the 
disease course. The fresh biopsies (n = 8–20 per UC patient) were representative of macroscopically 
active/inactive disease topography, as defined by Mayo endoscopic score (UC samples). Eligibility 
criteria for inclusion in this study were no history of human immunodeficiency virus. Age and 
gender were not exclusion factors (Table 2). Patients with UC were excluded if they had evidence of 
dysplasia or malignancy on colonoscopy with biopsy or positive to Clostridium difficile or infectious 
agents in stool assay in active UC cases. Cytomegalovirus (CMV) infection was also excluded using 
histopathology combined with immunohistochemistry against CMV antigens. Endoscopic 
assessment of the severity of UC was determined using the Mayo endoscopic subscore for UC as 
follows: normal or inactive disease—subscore 0; mild disease—subscore 1 (erythema, decreased 
vascular pattern, mild friability); moderate disease—subscore 2 (marked erythema, lack of vascular 
patterns, friability, erosions); severe disease—subscore 3 (spontaneous bleeding, ulceration) (30,31). 
Normal controls (n = 13) were randomly enrolled in the study (prospectively) and were represented 
by individuals that attend the gastroenterology department of CHP-HSA for a planned 
colonoscopy. The control group includes individuals without detectable colorectal lesions or 
previous history of IBD, colorectal hereditary syndromes or cancer (adenocarcinomas). In the 
patients of the control group, biopsies (8–20 biopsies per control used for the different purposes) 
were performed in mucosa without endoscopic abnormalities. 
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All specimens were subjected to histological examination and classification. All participants gave 
informed consent about all clinical procedures and research protocols were approved by the ethics 
committee of CHP/HSA, Portugal (233/12(179-DEFI/177-CES). 
Overall, we have analyzed 64 FFPE colonic biopsy samples. In addition, from a subset of UC patients 
and controls, we have also analyzed fresh colonic biopsies at different stages of disease course 
which were collected prospectively from 2011 to 2013. 
Tissue histochemistry 
A total of 64 FFPE colonic biopsies from normal controls (n = 13) and UC patients (n = 51) (16 Mayo 
subscore 0; 13 Mayo subscore 1; 14 Mayo subscore 2; 8 Mayo subscore 3) were analyzed by 
histochemistry in order to evaluate the expression of CD3 and the β1,6GlcNAc branched N-glycan 
structures. 
Identification of intestinal T lymphocytes at lamina propria was performed by CD3 
immunohistochemistry. Heat-induced antigen retrieval was performed and endogenous peroxidase 
activity was blocked. Slides were washed and incubated with swine normal serum (Dako) before 
incubation with rabbit IgG anti-human CD3 monoclonal antibody (clone EP449E, Thermo Scientific, 
diluted at 1:50) overnight, at 4°C. The slides were washed and incubated with biotinylated swine 
anti-rabbit secondary antibody (Dako). 
For evaluation of the expression of β1,6 GlcNAc branched structures, sections were incubated 1 h 
with biotinylated Phaseolus Vulgaris Leucoagglutinin (L-PHA) lectin that specifically recognizes the 
β1,6GlcNAc branched N-glycan structures (Vector Laboratories) diluted at 1:150. 
The avidin–biotin–peroxidase complex detection method was the Vectastain ABC Kit (Vector 
Laboratories). The chromogen used was 3,30-diaminobenzidine (DAB). Sections were 
counterstained with hematoxylin, dehydrated and mounted. Controls were incubated with PBS 
instead of the primary antibody or lectin. As positive control, sections of thymus (for CD3 
expression) and colon carcinoma (for L-PHA staining) were useThe percentage of expression of the 
β1,6 GlcNAc branched structures (L-PHA reactivity) in the intestinal lymphocytic infiltrate (T cells at 
lamina propria) positive to CD3 were evaluated by three independent observers (J.C.; S.S.P.; C.A.R.) 
and scored as follows: less than 25%; 25–50%; 50–75% and more than 75% of intestinal T 
lymphocytes at lamina propria stained. For statistical analysis, the percentage of expression of L-
PHA lectin reactivity was regrouped into two percentual categories (≤25%: low expression; and 
>25% to ≥75%: high expression) in order to increase the number of cases in each category and in 
this manner improve the statistical power of the tests. 
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The statistical relationship among variables was analyzed in StatView (SAS Institute) using tables of 
frequencies and their significance tested by the Chi-square (χ²). P-values less than 0.05 were 
considered a significant association. 
Isolation of LPLs 
LPLs were isolated from fresh colonic biopsies, following an adapted protocol (32). In order to 
isolate the LPLs, Percoll (Sigma) density gradients were used (1.05–1.09 g/ml). Lymphocytes were 
washed twice and cell yields were determined using a hemacytometer and cell viability was 
determined by trypan blue exclusion. After LPLs isolation, the levels of CD3 and/or TCR expression 
were evaluated by flow cytometry and/or imaging flow cytometry analysis. 
Flow cytometry 
To perform the characterization of the T cells subsets and activation state, isolated LPLs from 
normal individuals (n = 2 biological replicates) and UC patients (n = 2 biological replicates) were 
resuspended in 1000 μl of FACS Buffer (PBS1x containing 0.1% sodium azide and 2% BSA) following 
15 min of incubation at room temperature with the appropriate volume of monoclonal antibodies 
specific for CD45 (clone GA90, IgG2a mouse; Cytognos SL, Salamanca, Spain), CD3 (clone SK7, IgG1 
mouse; Becton Dickinson Biosciences, California, USA—BDB), TCR-alpha/beta (clone T10B9.1A-31, 
IgM mouse; BD Pharmingen, California, USA), CD4 (clone SK3, IgG2a mouse; BDB), CD8 (clone SK1, 
IgG1 mouse; BDB), CD45RO (clone UCHL-1BDB, IgG2a mouse; BDB) and HLA-DR (clone Immu-357, 
IgG1 mouse; Immunotech, Marseille, France—IOT), conjugated with orange cytognos 550 (OC550), 
pacific blue (PB), fluorescein isothiocyanate (FITC), peridinin-chlorophyll-protein complex Cy5.5 
tandem (PerCP-Cy5.5), allophycocyanin (APC), phycoerythrin (PE) and phycoerythrin-Cy7 tandem 
(PE-Cy7), respectively. Lastly, cells were fixed with 4% formaldehyde. Data acquisition was 
performed in a FACS Canto v.2 flow cytometer (BDB), using the FACSDiva software (BDB). 
Instrument alignment and standardization were done according to the recommendations of the 
Euroflow consortium. Data on a minimum of 2 × 105 events were acquired for each staining. The 
data were analyzed using the Infinicyt™ software (Cytognos SL). Lymphocytes were first identified 
and gated based on their bright CD45 expression and light scatter characteristics, and T cells were 
gated based on the expression of surface CD3. Afterwards, the major T-cell populations were 
identified and quantified, based on the type of TCR receptor (alpha/beta and gamma-delta), and 
CD4/CD8 molecules (CD4+, CD8+ and CD4−CD8− T cells). Finally, T cells were characterized for the 
expression of the activation-related markers, CD45RO and HLA-DR. Results were expressed as 
percentage (%) of cells that stained positively for each analyzed antigen, as well as the MFI due to 
antigen staining. 
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Imaging flow cytometry 
Isolated LPLs were centrifuged and the pellets resuspended in FACS Buffer. For TCR staining, cells 
were incubated with anti-TCRα/β mAb (clone BW242/412 mouse IgG2b) conjugated with R-
phycoerythrin (PE) (Miltenyi Biotech) diluted in FACS Buffer, on ice for 30 min, in the dark. For L-
PHA staining, cells were then incubated with L-PHA/FITC (4 µg/ml) (Vector Laboratories) and as 
negative control cells were incubated with Streptavidin-conjugated fluorescein isothiocyanate 
(FITC) (1 µg/ml) (Caltag Laboratories). Afterwards cells were washed, fixed with 4% formaldehyde 
and analyzed by imaging flow cytometry. 
Images of isolated cells were acquired on a 6-Channel ImageStreamX Imaging Flow Cytometer 
(Amnis, EMD Millipore) at the Bioimaging Center for Biomaterials and Regenerative Therapies 
(b.IMAGE, INEB, Porto, Portugal). Analysis was performed with IDEAS 5.0 (Amnis, EMD Millipore). 
Upon compensation, co-localization of the TCRα/β protein with L-PHA was determined with co-
localization wizard. The intensity of L-PHA staining within the TCRα/β positive events was also 
determined. The experiment was reproduced two times using cells from two different biological 
replicas. 
Western-blot and immunoprecipitation 
Evaluation of the total protein expression levels of TCR and CD3 was performed using 40 μg of TCL 
obtained from the whole fresh biopsy digestion. The samples were subjected to 12% SDS–PAGE 
electrophoresis and membranes were blocked before incubation with primary antibodies against 
TCRβ (mouse monoclonal antibody anti-human, Santa Cruz Biotechnology) (dilution 1:100) and 
CD3 (rat anti-human CD3ɛ mAb, Cell Signaling Technologies) (dilution 1:1000). The respective 
secondary antibodies used were goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) and donkey 
anti-rat IgG-HRP (Jackson ImmunoResearch). For loading control analysis, mouse IgG anti-tubulin 
(Sigma) was used. The target proteins were visualized using ECL reagent (GE Healthcare, Life 
Sciences). 
For TCR immunoprecipitation (IP), equal amounts of TCL obtained from the whole biopsy (500 µg) 
were precleared with protein G-sepharose beads (GE Healthcare, Life Sciences) and the 
supernatant was incubated overnight with rabbit anti-human TCRβ polyclonal antibody (Santa Cruz 
Biotechnology). The immune complexes were released by boiling and subjected to 12% SDS–PAGE. 
Membranes were blocked and probed with the primary anti-human TCRβ polyclonal antibody 
(dilution 1:100), and revealed with secondary antibody goat anti-rabbit IgG-HRP (Santa Cruz 
Biotechnology). For the β1,6 GlcNAc branched structures analysis on TCR, membranes were probed 
with biotinylated L-PHA or E-PHA (10 µg/ml) lectin. Immunoreactive bands were then visualized 
using the Vectorstain ABC kit and detection was performed by an ECL reagent. Quantitative 
analyses were performed by densitometric scanning of bands. 
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For L-PHA or E-PHA lectin blot analysis, 20 μg of LPLs protein lysate was used. Membranes were 
blocked before incubation with L-PHA or E-PHA lectin and bands were then visualized using the 
Vectorstain ABC kit. The detection was performed by an ECL reagent. For loading control, anti-
tubulin mAb was used. 
The experiments were reproduced at least three times. For all data comparisons, the Student's t-
test was used (two tailed, unequal variance). Results were considered statistically significant when P 
< 0.05. 
Real-time PCR 
Total RNA from isolated LPLs was extracted with Tri-Reagent (Sigma) or RNAqueous- Micro Kit 
(Applied Biosystems) according to the manufacturer's protocol. The quantitative real-time PCR 
(qRT-PCR) was performed using TaqMan Gene Expression Assays (Applied Biosystems). T 
lymphocytes total RNA were reversed transcribed to single-stranded cDNA using random hexamer 
primers and Superscript II Reverse Transcriptase (Invitrogen). qRT-PCR was carried out in triplicates 
using RNA source from three biological replicates (three normal individuals and three UC patients) 
and RNA pooled from four different normal controls and four different UC patients with active 
disease, for the target genes MGAT5 (Taqman probe: hs.00159136_m1, Applied Biosystems), 
MGAT3 (Taqman probe: hs.02379589_s1, using RNA source from 2 biological replicates: two normal 
individuals and two UC patients) and for the appropriated lymphocytes endogenous control 18S 
(Hs.PT.39a.22214856.g, Integrated DNA Technologies) and qRT-PCR reactions were performed on 
the ABI Prism 7000 Sequence Detection System. Data were analyzed by the comparative 2(−ΔΔCT) 
method (33). For all data comparisons, the Student's t-test was used (two-tailed, unequal variance). 
Results were considered statistically significant when P < 0.05. 
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Figure 1. Relationship between the levels of lymphocytic branched N-glycans expression and the 
inflammatory activity. (A) A total number of 64 colonic biopsies were analyzed for L-PHA 
expression in the intestinal lamina propria lymphocytic infiltrate positive to CD3 expression (B). 
There was a significant association (P , 0.0001) (Table 1) between the levels of lymphocytic 
branched N-glycans and the inflammatory activity. UC cases with active disease (Mayo subscore 
1,2,3) exhibit significantly lower levels (≤25%) of L-PHA lymphocytic expression compared with 
normal controls. (A) Illustrates that normal controls showed a significant increased reactivity of L-
PHA (.75%) in intestinal lymphocytic infiltrates CD3+ (left figures). On the contrary, right figures 
represent a case of active UC (Mayo subscore 3) showing a significant decrease of L-PHA reactivity 
in the lamina propria T lymphocytes (,25%) displaying heavy CD3 cell infiltrates. Amplification×
400. (The evaluation of the relationship between the expression of lymphocytic b1,6 GlcNAc 
branched structures and the inflammatory activity considering the four percentual categories 
(,25%; 25–50%; 50–75% and .75%) is statistically significant (CI:95%) and the table is provided in 
Supplementary Material, Table S1. The regrouping in two categories (Low and High) did not change 
the P value and did not influence statistically the results.) 
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Figure 2.TCR and CD3expression levels. (A) The results showed that activeUCpatients had 
significantly higher levels of bothTCRbandCD3expression compared with normal 
controls.UCpatients with severe disease (Mayo subscore 3) showed the highest levels 
ofTCRbandCD3 protein expression. InactiveUCpatients (Mayo endoscopic subscore 0) exhibited an 
increased TCRb and CD3 expression levels compared with normal controls. (B) Bar graphs, 
quantification of TCRb and CD3 densities normalized to tubulin. Results are described as 
mean+SEMof three independent experiments (Student’s t-test: ∗ P ≤ 0.05; ∗∗ P ≤ 0.01). In order to 
confirm the differential expression levels ofTCRbetween normal controls and activeUCpatients, 
LPLs obtained from the fresh colonic biopsies were analyzed for this marker by imaging flow 
cytometry (C). The percentage of cells expressing TCRab in gate R2 is indicated in brackets. The 
results showed that isolated LPLs from active UC patients express higher TCRabexpression levels 
compared with normal controls. Negative control refers to unstained cells (C). Lanes in (A) were on 
the different gels (black lines). Characterization of the Tcells subsets and activation state. (D) Flow 
cytometry dot-plots illustrating theCD4+ (red) andCD8+ (blue)Tcells populations and expression of 
CD45RO and HLA-DR on intestinal T cells from normal individuals (n ¼ 2 biological replicates) and 
UC patients (n ¼ 2 biological replicates). (E) Bar graphs, showing that CD3+T cells are 
predominantly represented by CD4+cells in UC patients and by CD8+cells in normal individuals (left 
graph).The activation state of CD3+ T cells was evaluated by the MFI due to antigen staining of the 
activation-related markers, HLA-DR and CD45RO. Intestinal T cells from UC patients exhibit a 
higher level of expression of these activation-related markers (right graph). 
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Figure 3. Alteration of intestinal TCR N-glycosylation in UC patients. (A) Protein lysates from the 
isolated LPLs were subjected to L-PHA lectin blot in order to evaluate the expression levels of b1,6 
GlcNAc branchedN-glycans on theTCR(39 kDa). The results showed a decreased TCRbranched 
glycosylation in UC patients compared with normal controls. Patients with severe disease (Mayo 
subscore 3) had the lowest branchedN-glycosylation modification of TCR. (B) Bar graphs, 
quantification of L-PHA densities on TCR band normalized to tubulin. Results are described as 
mean+SEM of three independent experiments (Student’s t-test:∗P ≤ 0.05; ∗∗P ≤ 0.01). (C) 
Immunoprecipiation of TCR followed by b1,6 GlcNAc branched N-glycans recognition. As observed 
in (A) and (B), the intestinalTCR from UC patients (with inactive and active disease) suffered a 
decreased modification with branched N-glycans compared with normal controls. UC patients with 
severe disease (Mayo subscore 3) showed the lowest levels of TCR branched N-glycosylation. (D) 
Bar graphs, amounts of branched N-glycan structures were determined from the ratios of densities 
of L-PHA reactivity normalized to TCR. Results are described as mean+SEM of three independent 
experiments (Student’s t-test: ∗ P ≤ 0.05; ∗∗ P ≤ 0.01; ∗∗∗ P ≤ 0.005). Lanes in (A) and (C) were on 
the different gels (black lines).  
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Figure 4. Imaging flow cytometry analysis of L-PHA membrane distribution in TCR positive cells. 
Intestinal LPLs were surface stained for TCRab and branched N-glycans (L-PHA) and analyzed on an 
ImageStreamX. (A) Examples of brightfield, L-PHA (green), TCRab (red) and overlaid images 
showing co-localization betweenTCRab and L-PHA. (B) Histogram representing the intensity of L-
PHA staining on theTCRab+ cells. (C) The intensity of L-PHA staining on the cell membrane of 
TCRab+ cells was measured by imaging flow cytometry, and normalized relatively to cells stained 
only with streptavidin-FITC (negative control). Data show the average of two independent 
experiments. Error bars represent the mean+SEM. The results indicate that UC patients with active 
disease (Mayo subscore ≥1) exhibit decreased levels of L-PHA staining at the cell membrane of 
TCRab+ cells comparing with normal controls. 
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Figure 5. Deficiency ofMGAT5gene expression inLPLsfromUCpatients. (A) qRT-PCRanalysis for 
mRNA expression ofMGAT5from intestinal LPLsfrom normal controls and activeUCpatients (Mayo 
subscore 1,2,3). Results in (A) are an average of three independent experiments, performed in 
triplicate, usingRNAfrom three independent normal controls and three independent active UC 
patients. (B) Represents the average of two independent experiments using RNA of intestinal LPLs 
pooled from four different normal controls and four different UC patients, performed in triplicate. 
There is a significant decrease of MGAT5 mRNA expression from intestinal LPLs of UC patients 
(with active disease) compared with normal controls. The mRNA expression levels are expressed as 
mean+SEM (Student’s t-test: ∗ P ≤ 0.01). 
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Figure 6.A model for the dysregulation of TCR N-glycosylation in UC. In intestinal homeostasis and 
under normal conditions, the T cell activation (TCR signaling) induces up-regulation of MGAT5 gene 
which in turns leads to GnT-V-mediated glycosylation of the TCR. The increased b1,6GlcNAc 
branching synthesis on TCR, catalyzed by GnT-V, negatively regulates T cell response promoting 
growth arrest of T cells by raising T cell activation thresholds via limiting TCR clustering at the 
immunesynapse. ThisGnT-V-mediated branched glycosylation of theTCRis associated with a 
controlledimmune response. InUCpatients,wepropose the existence of a dysregulation of the 
intestinal TCR N-glycosylation catalyzed by GnT-V. Alterations on the transcription levels of 
MGAT5 glycogene of the intestinal T cells appear to underlie the deficiency of GnT-V-mediated 
glycosylation on the TCR. This dysregulation of TCR branched N-glycosylation contribute to 
decrease the threshold of T-cell activation leading to a hyperimmune response, which is a feature of 
UC patients. 
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Table 1. Relationship between L-PHA expression in intestinal lymphocytic infiltrate and the 
inflammatory activity 
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Table 2. Patients’ characteristics 
 
 
 
 
 
 
 
